Lamivudine & Zidovudine

Lamivudine & Zidovudine

Form: Tablet

Strength: Lamivudine 150 mg + Zidovudine 300 mg

Reference Brands: Combivir®(US/ EU)

Category: Anti Viral

Lamivudine & Zidovudine Tablets are a fixed-dose combination of two key NRTIs used in the management of HIV-1 infection. Each tablet contains Lamivudine 150 mg and Zidovudine 300 mg, offering dual-action antiviral activity in a convenient dosing format. Available under brands like Combivir®, this formulation is widely used in global HIV treatment protocols. Through PharmaB2B platforms, healthcare providers and procurement agencies can access bulk supplies from WHO-GMP and USFDA-approved manufacturers. Ideal for tenders, NGOs, and institutional buyers, this ARV combo supports consistent, cost-effective treatment. Connect with trusted suppliers to ensure high-quality antiretrovirals and uninterrupted patient care.

Get Enquiry Back to Listing
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.

Related Products

Zanamivir

Strength: 5 mg/blister

Form: Inhalation powder

Reference Brands: Relenza(EU & US)

View Details Get Enquiry
Oseltamivir Phosphate Capsule

Strength: Capsule- 30 mg, 45 mg, 75 mg; Oral Suspension - 6 mg/mL (reconstituted)

Form: Capsules and Oral solution

Reference Brands: Tamiflu(EU & US)

View Details Get Enquiry
Amantadine

Strength: Tab -100 mg; Capsule- 100 mg; Oral solution - 50 mg/5 mL; Extended-release capsule (ER) - 129 mg, 193 mg

Form: Tablet; Capsule; Oral Solution and ER Capsule

Reference Brands: Symmetrel(EU & US); Osmolex ER(US), Gocovri(US)

View Details Get Enquiry
Glecaprevir + Pibrentasvir

Strength: Glecaprevir- 100 mg + Pibrentasvir - 40 mg

Form: Tablet

Reference Brands: Mavyret (US); Maviret (EU)

View Details Get Enquiry

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.